Publications & News

Epizyme Announces Closing of Public Offering of Common Stock

September 29, 2017

On September 19, 2017, Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, announced the closing of its public offering of 10,557,000 shares of its common stock at a price of $15.25 per share, before underwriting discounts. The shares of common stock issued and sold in the offering at the closing include 1,377,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price less the underwriting discount. The aggregate net proceeds before expenses to Epizyme from the offering are approximately $151.3 million, after deducting underwriting discounts and commissions.

Stuart Falber the led the WilmerHale team representing Epizyme in this transaction, which also included Molly Fox, Emily Gainor and Nils Remole.

Epizyme's press release is available at www.epizyme.com.